5 key lessons learned in the US about weight loss drugs
With obesity and related chronic diseases on the rise worldwide, GLP-1 receptor agonists (used to treat type 2 diabetes and obesity) – namely Eli Lilly’s Zepbound® and Mounjaro®, and Novo...
Sean Duffy is the Co-founder and CEO of Omada Health, a between-visit care provider for prediabetes/obesity, diabetes, hypertension, and musculoskeletal disorders. He has dedicated his professional life to harnessing the cross-functional impact of technology, design, and care delivery to transform care experiences for patients. As a former MD/MBA candidate at Harvard, he also holds a BS in neuroscience from Columbia University. He has written extensively about digital health and the future of healthcare in The New England Journal of Medicine, The Wall Street Journal, Forbes, and TechCrunch, among other publications. Prior to Omada, Sean worked at both Google and IDEO.